Author(s): Roberts JL, Ortonne JP, Tan JK, Jaracz E, Frankel E Alefacept Cli
Abstract Share this page
Abstract BACKGROUND: Safety and efficacy of up to 3 courses of alefacept intramuscular (IM) in the treatment of chronic plaque psoriasis have been demonstrated in earlier trials. OBJECTIVE: We sought to determine the safety and efficacy of up to 5 courses of alefacept IM in treating plaque psoriasis. METHODS: A standard treatment course was defined as 15 mg of alefacept IM once weekly for 12 weeks, followed by 12 weeks of treatment-free observation. Patients with chronic plaque psoriasis, who had previously received alefacept IM, received up to 3 additional courses (A, B, and C). Efficacy was evaluated by Physician Global Assessment. RESULTS: Safety profiles were similar to those for a single course of treatment. There were no cumulative adverse effects. At 2 weeks postdosing, 16\%, 22\%, and 19\% of patients were rated clear or almost clear by Physician Global Assessment in courses A, B, and C, respectively, with 35\%, 42\%, and 42\% achieving this response at any time during these courses. Patients who achieved clear or almost clear at 2 weeks postdosing remained so for a median duration of 214 and 126 days after courses A and B, respectively. LIMITATIONS: This was an extension study and therefore contained no control group. CONCLUSIONS: Up to 5 courses of alefacept IM may provide extended treatment-free, symptom-free periods in responders while maintaining the safety profile. Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
This article was published in J Am Acad Dermatol
and referenced in Immunotherapy: Open Access